NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retention Rate of Acalabrutinib in a Non-interventional Setting

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Chronic Lymphocytic Leukaemia (CLL)

Countries: Germany

Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of CLL
* Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives
* Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy.
* Provision of signed informed consent form

Exclusion Criteria:

* Current or planned participation in an interventional clinical trial
* Contraindications to treatment with acalabrutinib according to the current SmPC
* Pregnancy or breast feeding
* Disease progression on prior BTKi therapy
* Start of acalabrutinib therapy more than 28 days prior to enrolment

Locations (61)

D Ren, Germany, Germany
Herrsching am Ammersee, Germany, Germany
L Rrach, Germany, Germany
M Nchen, Germany, Germany
M Nchen, Germany, Germany
N Rnberg, Germany, Germany
Neustadt Am R Benberge, Germany, Germany
Saarbr Cken, Germany, Germany
Sindelfinden, Germany, Germany
W Rselen, Germany, Germany
Amberg, Germany
Aschaffenburg, Germany
Augsburg, Germany
Bad Homburg, Germany
Bad Liebenwerda, Germany
Bautzen, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Bonn, Germany
Dachau, Germany
Delitzsch, Germany
Dessau, Germany
Dortmund, Germany
Erfurt, Germany
Erfurt, Germany
Essen, Germany
Frankfurt am Main, Germany
Frankfurt am Main, Germany
Garbsen, Germany
+ 31 more on CT.gov